No Data
HEARTCARE-B: ANNUAL REPORT 2024
The industry is hotly discussing the future trends of nuclear medicine, will Hybrid NewCo become a new model for the RDC Industry to venture abroad? | Industry Observation
① Today, the 2025 Future XDC New Drug Conference is held in Chengdu; ② Executives from companies such as Baillie Tianheng and Kelun Botai, along with numerous experts and scholars in the industry, will jointly discuss cutting-edge technologies in ADC/nuclear drug development, overseas strategies, and other Topics.
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
Earnings Conference Focus | Xinwei Medical-B (06609.HK): Overseas revenue growth exceeds six times, entering a new stage of breakeven.
Recently, Shanghai Xinwei Medical Technology Co., Ltd. (hereinafter referred to as "Xinwei Medical" or "the company") announced its annual performance report for the year 2024.
Xinwei Medical-B (06609.HK) significantly reduced its loss by 88% to 12 million yuan for the fiscal year 2024.
On March 27, Gelonghui reported that Xinyi Medical-B (06609.HK) announced an income of RMB 0.278 billion for the 2024 fiscal year, representing a year-on-year increase of 19.6%. Despite the impact of bulk procurement prices and competition leading to a decrease in gross margin, the company's pre-tax loss narrowed significantly to RMB 12 million, down 88.3% year-on-year. With the expansion of the business scale and the effectiveness of cost control and efficiency enhancement measures, the expense ratio for sales and distribution expenses and administrative expenses fell to 49.6% (2023: 66.2%). During the year, to adapt to the rapidly changing market environment, the company continued to push forward.
